Lung Cancer Clinical Trials in Colorado

Showing 141-160 of 292 trials

Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations

NCT04161391

A phase 1/2, first-in-human, open-label study to determine the safety, tolerability, PK, and preliminary efficacy of the novel RET/SRC inhibitor TPX-0046 in adult subjects with advanced or metastatic solid tumors harboring RET mutations or alterations. The study consists of three portions: 1) Phase 1 Dose Escalation and Food Effect Sub-study, and 2) Phase 1 dose expansion and 3) Phase 2 efficacy evaluation.

Non Small Cell Lung CancerMedullary Thyroid CancerRET Gene Mutation+2 more

Turning Point Therapeutics, Inc.41 participantsStarted Dec 2019

La Jolla, California, United States • Orange, California, United States • Aurora, Colorado, United States +18 more locations

COMPLETED50 miles

Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer

NCT03892096

Accrue samples for the further development and clinical validation of a blood-based cell-free DNA (cfDNA) quantitative real-time polymerase chain reaction (qPCR) assay as a potential biomarker for early non-response to therapy in stage IV non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and breast cancer (BC).

Metastatic Non-Small Cell Lung CarcinomaMetastatic Colorectal CancerMetastatic Breast Cancer

Cadex Genomics130 participantsStarted Mar 2019

Little Rock, Arkansas, United States • Sunnyvale, California, United States • Denver, Colorado, United States +9 more locations

Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations

Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer

Lung Cancer Trials in Other Cities

Pilot Study of High Risk Lung Cancer Screening

An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors

A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib

A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab

Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer

AN0025 and Pembrolizumab Combination in Advanced Solid Tumors

OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure

A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

Survival Prolongation by Rationale Innovative Genomics

Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors

Study of PF-07263689 in Participants With Selected Advanced Solid Tumors

Study of the CD40 Agonistic Monoclonal Antibody APX005M

Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer

Phase I/IIa Study of H002 in NSCLC With Active EGFR Mutation

Other Conditions in Colorado